Chardan Capital Reiterates Buy on Coya Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Coya Therapeutics (NASDAQ:COYA) and maintained an $11 price target.
August 09, 2023 | 8:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Coya Therapeutics and maintained an $11 price target.
The reiteration of a 'Buy' rating by Chardan Capital indicates their continued confidence in Coya Therapeutics. The maintained price target of $11 suggests they believe the stock is undervalued at current prices. This could potentially lead to increased investor interest and upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100